Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

A message from ASCO'S President. It has been forty years since President Richard Nixon signed the National Cancer Act of 1971, which many view as the nation's declaration of the "War on Cancer." The bill has led to major investments in cancer research and significant increases in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical oncology 2012-01, Vol.30 (1), p.88-109
Hauptverfasser: VOGELZANG, Nicholas J, BENOWITZ, Steven I, PATEL, Jyoti D, ROTH, Bruce J, SAMLOWSKI, Wolfram E, SEIDMAN, Andrew D, TAP, William D, TEMEL, Jennifer S, VON ROENN, Jamie H, KRIS, Mark G, ADAMS, Sylvia, AGHAJANIAN, Carol, CHANG, Susan Marina, DREYER, Zoann Eckert, JANNE, Pasi A, KO, Andrew H, MASTERS, Greg A, ODENIKE, Olatoyosi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 109
container_issue 1
container_start_page 88
container_title Journal of clinical oncology
container_volume 30
creator VOGELZANG, Nicholas J
BENOWITZ, Steven I
PATEL, Jyoti D
ROTH, Bruce J
SAMLOWSKI, Wolfram E
SEIDMAN, Andrew D
TAP, William D
TEMEL, Jennifer S
VON ROENN, Jamie H
KRIS, Mark G
ADAMS, Sylvia
AGHAJANIAN, Carol
CHANG, Susan Marina
DREYER, Zoann Eckert
JANNE, Pasi A
KO, Andrew H
MASTERS, Greg A
ODENIKE, Olatoyosi
description A message from ASCO'S President. It has been forty years since President Richard Nixon signed the National Cancer Act of 1971, which many view as the nation's declaration of the "War on Cancer." The bill has led to major investments in cancer research and significant increases in cancer survival. Today, two-thirds of patients survive at least five years after being diagnosed with cancer compared with just half of all diagnosed patients surviving five years after diagnosis in 1975. The research advances detailed in this year's Clinical Cancer Advances demonstrate that improvements in cancer screening, treatment, and prevention save and improve lives. But although much progress has been made, cancer remains one of the world's most serious health problems. In the United States, the disease is expected to become the nation's leading cause of death in the years ahead as our population ages. I believe we can accelerate the pace of progress, provided that everyone involved in cancer care works together to achieve this goal. It is this viewpoint that has shaped the theme for my presidential term: Collaborating to Conquer Cancer. In practice, this means that physicians and researchers must learn from every patient's experience, ensure greater collaboration between members of a patient's medical team, and involve more patients in the search for cures through clinical trials. Cancer advocates, insurers, and government agencies also have important roles to play. Today, we have an incredible opportunity to improve the quality of cancer care by drawing lessons from the real-world experiences of patients. The American Society of Clinical Oncology (ASCO) is taking the lead in this area, in part through innovative use of health information technology. In addition to our existing quality initiatives, ASCO is working with partners to develop a comprehensive rapid-learning system for cancer care. When complete, this system will provide physicians with personalized, real-time information that can inform the care of every patient with cancer as well as connect patients with their entire medical teams. The rapid learning system will form a continuous cycle of learning: securely capturing data from every patient at the point of care, drawing on evidence-based guidelines, and evaluating quality of care against those standards and the outcomes of other patients. Clinical trials are another area in which collaboration is critical. Increasing clinical trial participation will require
doi_str_mv 10.1200/JCO.2011.40.1919
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_913317028</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>913317028</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-79c7d38f5567ff932b3f51138ae45574a4fd41401cdcb6d431e092b6823ca4403</originalsourceid><addsrcrecordid>eNpFkEtvGyEURlHVqHHS7ruqWLTqahwuD8N0Nxo1aatIjvqQukOYYWyiGXBgnMr_Plh20hXocr7vioPQeyBzoIRc_WiXc0oA5rwMaqhfoRkIKisphXiNZkQyWoFif8_RRc73hABXTLxB55QCl5ItZuixHXzw1gy4NcG6hJvu8XDJ-ND7BTch7MrjT7eNacIx4LsU18nljJu18SFPz7nrFEc8bRxuRpdKYcC_ovVu2uPY45cly2DjENf7t-isN0N2707nJfpz_fV3-626Xd58b5vbynLKpkrWVnZM9UIsZN_XjK5YLwCYMo4LIbnhfceBE7CdXS06zsCRmq4WijJrOCfsEn0-9m5TfNi5POnRZ-uGwQQXd1nXwBhIQlUhyZG0KeacXK-3yY8m7TUQfZCti2x9kKJ5GRTZJfLhVL5bja57CTzbLcCnE2By-X2fiiqf_3OCKyU4FO7jkdv49eafT07n0QxDqaX63kZW9mml2BO735Ja</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>913317028</pqid></control><display><type>article</type><title>Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology</title><source>MEDLINE</source><source>American Society of Clinical Oncology Online Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>VOGELZANG, Nicholas J ; BENOWITZ, Steven I ; PATEL, Jyoti D ; ROTH, Bruce J ; SAMLOWSKI, Wolfram E ; SEIDMAN, Andrew D ; TAP, William D ; TEMEL, Jennifer S ; VON ROENN, Jamie H ; KRIS, Mark G ; ADAMS, Sylvia ; AGHAJANIAN, Carol ; CHANG, Susan Marina ; DREYER, Zoann Eckert ; JANNE, Pasi A ; KO, Andrew H ; MASTERS, Greg A ; ODENIKE, Olatoyosi</creator><creatorcontrib>VOGELZANG, Nicholas J ; BENOWITZ, Steven I ; PATEL, Jyoti D ; ROTH, Bruce J ; SAMLOWSKI, Wolfram E ; SEIDMAN, Andrew D ; TAP, William D ; TEMEL, Jennifer S ; VON ROENN, Jamie H ; KRIS, Mark G ; ADAMS, Sylvia ; AGHAJANIAN, Carol ; CHANG, Susan Marina ; DREYER, Zoann Eckert ; JANNE, Pasi A ; KO, Andrew H ; MASTERS, Greg A ; ODENIKE, Olatoyosi</creatorcontrib><description>A message from ASCO'S President. It has been forty years since President Richard Nixon signed the National Cancer Act of 1971, which many view as the nation's declaration of the "War on Cancer." The bill has led to major investments in cancer research and significant increases in cancer survival. Today, two-thirds of patients survive at least five years after being diagnosed with cancer compared with just half of all diagnosed patients surviving five years after diagnosis in 1975. The research advances detailed in this year's Clinical Cancer Advances demonstrate that improvements in cancer screening, treatment, and prevention save and improve lives. But although much progress has been made, cancer remains one of the world's most serious health problems. In the United States, the disease is expected to become the nation's leading cause of death in the years ahead as our population ages. I believe we can accelerate the pace of progress, provided that everyone involved in cancer care works together to achieve this goal. It is this viewpoint that has shaped the theme for my presidential term: Collaborating to Conquer Cancer. In practice, this means that physicians and researchers must learn from every patient's experience, ensure greater collaboration between members of a patient's medical team, and involve more patients in the search for cures through clinical trials. Cancer advocates, insurers, and government agencies also have important roles to play. Today, we have an incredible opportunity to improve the quality of cancer care by drawing lessons from the real-world experiences of patients. The American Society of Clinical Oncology (ASCO) is taking the lead in this area, in part through innovative use of health information technology. In addition to our existing quality initiatives, ASCO is working with partners to develop a comprehensive rapid-learning system for cancer care. When complete, this system will provide physicians with personalized, real-time information that can inform the care of every patient with cancer as well as connect patients with their entire medical teams. The rapid learning system will form a continuous cycle of learning: securely capturing data from every patient at the point of care, drawing on evidence-based guidelines, and evaluating quality of care against those standards and the outcomes of other patients. Clinical trials are another area in which collaboration is critical. Increasing clinical trial participation will require commitment across the cancer community from physicians, patients, insurers, hospitals, and industry. A 2010 report by the Institute of Medicine described challenges to participation in trials by both physicians and patients and provided recommendations for revitalizing clinical trials conducted through the National Cancer Institute's Cooperative Group Program. ASCO has pledged its support for the full implementation of these recommendations. More broadly, ASCO recently outlined a bold vision for translational and clinical cancer research for the next decade and made recommendations to achieve that vision. Accelerating Progress Against Cancer: ASCO's Blueprint for Transforming Clinical and Translational Research, released in November, calls for a research system that takes full advantage of today's scientific and technologic opportunities and sets a high-level agenda for policy makers, regulators, and advocates. Cancer research has transformed cancer care in the past forty years, and this year's Clinical Cancer Advances illustrates how far we have come in the past year alone. We now have a tremendous opportunity to use today's knowledge and collaborate across all facets of cancer care to conquer this deadly disease. Michael P. Link, MD President American Society of Clinical Oncology.</description><identifier>ISSN: 0732-183X</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.2011.40.1919</identifier><identifier>PMID: 22147736</identifier><language>eng</language><publisher>Alexandria, VA: American Society of Clinical Oncology</publisher><subject>Adult ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Biomarkers, Tumor - metabolism ; Chemotherapy, Adjuvant ; Child ; Clinical Trials as Topic - trends ; Drug Approval ; Early Detection of Cancer - methods ; Educational Status ; Female ; Genetic Predisposition to Disease ; Health Care Reform ; Health Policy - trends ; Health Services Accessibility ; Healthcare Disparities ; Hospice Care ; Humans ; Immunotherapy ; Male ; Medical Oncology - trends ; Medical sciences ; Mutation ; Neoplasms - diagnosis ; Neoplasms - drug therapy ; Neoplasms - metabolism ; Neoplasms - mortality ; Neoplasms - prevention &amp; control ; Precision Medicine ; Primary Prevention - methods ; Quality of Life ; Radiotherapy, Adjuvant ; Research - trends ; Secondary Prevention - methods ; Socioeconomic Factors ; Terminal Care ; Tomography, X-Ray Computed ; Tumors ; United States - epidemiology</subject><ispartof>Journal of clinical oncology, 2012-01, Vol.30 (1), p.88-109</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-79c7d38f5567ff932b3f51138ae45574a4fd41401cdcb6d431e092b6823ca4403</citedby><cites>FETCH-LOGICAL-c423t-79c7d38f5567ff932b3f51138ae45574a4fd41401cdcb6d431e092b6823ca4403</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,3730,4025,27928,27929,27930</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=25488541$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22147736$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>VOGELZANG, Nicholas J</creatorcontrib><creatorcontrib>BENOWITZ, Steven I</creatorcontrib><creatorcontrib>PATEL, Jyoti D</creatorcontrib><creatorcontrib>ROTH, Bruce J</creatorcontrib><creatorcontrib>SAMLOWSKI, Wolfram E</creatorcontrib><creatorcontrib>SEIDMAN, Andrew D</creatorcontrib><creatorcontrib>TAP, William D</creatorcontrib><creatorcontrib>TEMEL, Jennifer S</creatorcontrib><creatorcontrib>VON ROENN, Jamie H</creatorcontrib><creatorcontrib>KRIS, Mark G</creatorcontrib><creatorcontrib>ADAMS, Sylvia</creatorcontrib><creatorcontrib>AGHAJANIAN, Carol</creatorcontrib><creatorcontrib>CHANG, Susan Marina</creatorcontrib><creatorcontrib>DREYER, Zoann Eckert</creatorcontrib><creatorcontrib>JANNE, Pasi A</creatorcontrib><creatorcontrib>KO, Andrew H</creatorcontrib><creatorcontrib>MASTERS, Greg A</creatorcontrib><creatorcontrib>ODENIKE, Olatoyosi</creatorcontrib><title>Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology</title><title>Journal of clinical oncology</title><addtitle>J Clin Oncol</addtitle><description>A message from ASCO'S President. It has been forty years since President Richard Nixon signed the National Cancer Act of 1971, which many view as the nation's declaration of the "War on Cancer." The bill has led to major investments in cancer research and significant increases in cancer survival. Today, two-thirds of patients survive at least five years after being diagnosed with cancer compared with just half of all diagnosed patients surviving five years after diagnosis in 1975. The research advances detailed in this year's Clinical Cancer Advances demonstrate that improvements in cancer screening, treatment, and prevention save and improve lives. But although much progress has been made, cancer remains one of the world's most serious health problems. In the United States, the disease is expected to become the nation's leading cause of death in the years ahead as our population ages. I believe we can accelerate the pace of progress, provided that everyone involved in cancer care works together to achieve this goal. It is this viewpoint that has shaped the theme for my presidential term: Collaborating to Conquer Cancer. In practice, this means that physicians and researchers must learn from every patient's experience, ensure greater collaboration between members of a patient's medical team, and involve more patients in the search for cures through clinical trials. Cancer advocates, insurers, and government agencies also have important roles to play. Today, we have an incredible opportunity to improve the quality of cancer care by drawing lessons from the real-world experiences of patients. The American Society of Clinical Oncology (ASCO) is taking the lead in this area, in part through innovative use of health information technology. In addition to our existing quality initiatives, ASCO is working with partners to develop a comprehensive rapid-learning system for cancer care. When complete, this system will provide physicians with personalized, real-time information that can inform the care of every patient with cancer as well as connect patients with their entire medical teams. The rapid learning system will form a continuous cycle of learning: securely capturing data from every patient at the point of care, drawing on evidence-based guidelines, and evaluating quality of care against those standards and the outcomes of other patients. Clinical trials are another area in which collaboration is critical. Increasing clinical trial participation will require commitment across the cancer community from physicians, patients, insurers, hospitals, and industry. A 2010 report by the Institute of Medicine described challenges to participation in trials by both physicians and patients and provided recommendations for revitalizing clinical trials conducted through the National Cancer Institute's Cooperative Group Program. ASCO has pledged its support for the full implementation of these recommendations. More broadly, ASCO recently outlined a bold vision for translational and clinical cancer research for the next decade and made recommendations to achieve that vision. Accelerating Progress Against Cancer: ASCO's Blueprint for Transforming Clinical and Translational Research, released in November, calls for a research system that takes full advantage of today's scientific and technologic opportunities and sets a high-level agenda for policy makers, regulators, and advocates. Cancer research has transformed cancer care in the past forty years, and this year's Clinical Cancer Advances illustrates how far we have come in the past year alone. We now have a tremendous opportunity to use today's knowledge and collaborate across all facets of cancer care to conquer this deadly disease. Michael P. Link, MD President American Society of Clinical Oncology.</description><subject>Adult</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Chemotherapy, Adjuvant</subject><subject>Child</subject><subject>Clinical Trials as Topic - trends</subject><subject>Drug Approval</subject><subject>Early Detection of Cancer - methods</subject><subject>Educational Status</subject><subject>Female</subject><subject>Genetic Predisposition to Disease</subject><subject>Health Care Reform</subject><subject>Health Policy - trends</subject><subject>Health Services Accessibility</subject><subject>Healthcare Disparities</subject><subject>Hospice Care</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Male</subject><subject>Medical Oncology - trends</subject><subject>Medical sciences</subject><subject>Mutation</subject><subject>Neoplasms - diagnosis</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - metabolism</subject><subject>Neoplasms - mortality</subject><subject>Neoplasms - prevention &amp; control</subject><subject>Precision Medicine</subject><subject>Primary Prevention - methods</subject><subject>Quality of Life</subject><subject>Radiotherapy, Adjuvant</subject><subject>Research - trends</subject><subject>Secondary Prevention - methods</subject><subject>Socioeconomic Factors</subject><subject>Terminal Care</subject><subject>Tomography, X-Ray Computed</subject><subject>Tumors</subject><subject>United States - epidemiology</subject><issn>0732-183X</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkEtvGyEURlHVqHHS7ruqWLTqahwuD8N0Nxo1aatIjvqQukOYYWyiGXBgnMr_Plh20hXocr7vioPQeyBzoIRc_WiXc0oA5rwMaqhfoRkIKisphXiNZkQyWoFif8_RRc73hABXTLxB55QCl5ItZuixHXzw1gy4NcG6hJvu8XDJ-ND7BTch7MrjT7eNacIx4LsU18nljJu18SFPz7nrFEc8bRxuRpdKYcC_ovVu2uPY45cly2DjENf7t-isN0N2707nJfpz_fV3-626Xd58b5vbynLKpkrWVnZM9UIsZN_XjK5YLwCYMo4LIbnhfceBE7CdXS06zsCRmq4WijJrOCfsEn0-9m5TfNi5POnRZ-uGwQQXd1nXwBhIQlUhyZG0KeacXK-3yY8m7TUQfZCti2x9kKJ5GRTZJfLhVL5bja57CTzbLcCnE2By-X2fiiqf_3OCKyU4FO7jkdv49eafT07n0QxDqaX63kZW9mml2BO735Ja</recordid><startdate>20120101</startdate><enddate>20120101</enddate><creator>VOGELZANG, Nicholas J</creator><creator>BENOWITZ, Steven I</creator><creator>PATEL, Jyoti D</creator><creator>ROTH, Bruce J</creator><creator>SAMLOWSKI, Wolfram E</creator><creator>SEIDMAN, Andrew D</creator><creator>TAP, William D</creator><creator>TEMEL, Jennifer S</creator><creator>VON ROENN, Jamie H</creator><creator>KRIS, Mark G</creator><creator>ADAMS, Sylvia</creator><creator>AGHAJANIAN, Carol</creator><creator>CHANG, Susan Marina</creator><creator>DREYER, Zoann Eckert</creator><creator>JANNE, Pasi A</creator><creator>KO, Andrew H</creator><creator>MASTERS, Greg A</creator><creator>ODENIKE, Olatoyosi</creator><general>American Society of Clinical Oncology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120101</creationdate><title>Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology</title><author>VOGELZANG, Nicholas J ; BENOWITZ, Steven I ; PATEL, Jyoti D ; ROTH, Bruce J ; SAMLOWSKI, Wolfram E ; SEIDMAN, Andrew D ; TAP, William D ; TEMEL, Jennifer S ; VON ROENN, Jamie H ; KRIS, Mark G ; ADAMS, Sylvia ; AGHAJANIAN, Carol ; CHANG, Susan Marina ; DREYER, Zoann Eckert ; JANNE, Pasi A ; KO, Andrew H ; MASTERS, Greg A ; ODENIKE, Olatoyosi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-79c7d38f5567ff932b3f51138ae45574a4fd41401cdcb6d431e092b6823ca4403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Chemotherapy, Adjuvant</topic><topic>Child</topic><topic>Clinical Trials as Topic - trends</topic><topic>Drug Approval</topic><topic>Early Detection of Cancer - methods</topic><topic>Educational Status</topic><topic>Female</topic><topic>Genetic Predisposition to Disease</topic><topic>Health Care Reform</topic><topic>Health Policy - trends</topic><topic>Health Services Accessibility</topic><topic>Healthcare Disparities</topic><topic>Hospice Care</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Male</topic><topic>Medical Oncology - trends</topic><topic>Medical sciences</topic><topic>Mutation</topic><topic>Neoplasms - diagnosis</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - metabolism</topic><topic>Neoplasms - mortality</topic><topic>Neoplasms - prevention &amp; control</topic><topic>Precision Medicine</topic><topic>Primary Prevention - methods</topic><topic>Quality of Life</topic><topic>Radiotherapy, Adjuvant</topic><topic>Research - trends</topic><topic>Secondary Prevention - methods</topic><topic>Socioeconomic Factors</topic><topic>Terminal Care</topic><topic>Tomography, X-Ray Computed</topic><topic>Tumors</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VOGELZANG, Nicholas J</creatorcontrib><creatorcontrib>BENOWITZ, Steven I</creatorcontrib><creatorcontrib>PATEL, Jyoti D</creatorcontrib><creatorcontrib>ROTH, Bruce J</creatorcontrib><creatorcontrib>SAMLOWSKI, Wolfram E</creatorcontrib><creatorcontrib>SEIDMAN, Andrew D</creatorcontrib><creatorcontrib>TAP, William D</creatorcontrib><creatorcontrib>TEMEL, Jennifer S</creatorcontrib><creatorcontrib>VON ROENN, Jamie H</creatorcontrib><creatorcontrib>KRIS, Mark G</creatorcontrib><creatorcontrib>ADAMS, Sylvia</creatorcontrib><creatorcontrib>AGHAJANIAN, Carol</creatorcontrib><creatorcontrib>CHANG, Susan Marina</creatorcontrib><creatorcontrib>DREYER, Zoann Eckert</creatorcontrib><creatorcontrib>JANNE, Pasi A</creatorcontrib><creatorcontrib>KO, Andrew H</creatorcontrib><creatorcontrib>MASTERS, Greg A</creatorcontrib><creatorcontrib>ODENIKE, Olatoyosi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VOGELZANG, Nicholas J</au><au>BENOWITZ, Steven I</au><au>PATEL, Jyoti D</au><au>ROTH, Bruce J</au><au>SAMLOWSKI, Wolfram E</au><au>SEIDMAN, Andrew D</au><au>TAP, William D</au><au>TEMEL, Jennifer S</au><au>VON ROENN, Jamie H</au><au>KRIS, Mark G</au><au>ADAMS, Sylvia</au><au>AGHAJANIAN, Carol</au><au>CHANG, Susan Marina</au><au>DREYER, Zoann Eckert</au><au>JANNE, Pasi A</au><au>KO, Andrew H</au><au>MASTERS, Greg A</au><au>ODENIKE, Olatoyosi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology</atitle><jtitle>Journal of clinical oncology</jtitle><addtitle>J Clin Oncol</addtitle><date>2012-01-01</date><risdate>2012</risdate><volume>30</volume><issue>1</issue><spage>88</spage><epage>109</epage><pages>88-109</pages><issn>0732-183X</issn><eissn>1527-7755</eissn><abstract>A message from ASCO'S President. It has been forty years since President Richard Nixon signed the National Cancer Act of 1971, which many view as the nation's declaration of the "War on Cancer." The bill has led to major investments in cancer research and significant increases in cancer survival. Today, two-thirds of patients survive at least five years after being diagnosed with cancer compared with just half of all diagnosed patients surviving five years after diagnosis in 1975. The research advances detailed in this year's Clinical Cancer Advances demonstrate that improvements in cancer screening, treatment, and prevention save and improve lives. But although much progress has been made, cancer remains one of the world's most serious health problems. In the United States, the disease is expected to become the nation's leading cause of death in the years ahead as our population ages. I believe we can accelerate the pace of progress, provided that everyone involved in cancer care works together to achieve this goal. It is this viewpoint that has shaped the theme for my presidential term: Collaborating to Conquer Cancer. In practice, this means that physicians and researchers must learn from every patient's experience, ensure greater collaboration between members of a patient's medical team, and involve more patients in the search for cures through clinical trials. Cancer advocates, insurers, and government agencies also have important roles to play. Today, we have an incredible opportunity to improve the quality of cancer care by drawing lessons from the real-world experiences of patients. The American Society of Clinical Oncology (ASCO) is taking the lead in this area, in part through innovative use of health information technology. In addition to our existing quality initiatives, ASCO is working with partners to develop a comprehensive rapid-learning system for cancer care. When complete, this system will provide physicians with personalized, real-time information that can inform the care of every patient with cancer as well as connect patients with their entire medical teams. The rapid learning system will form a continuous cycle of learning: securely capturing data from every patient at the point of care, drawing on evidence-based guidelines, and evaluating quality of care against those standards and the outcomes of other patients. Clinical trials are another area in which collaboration is critical. Increasing clinical trial participation will require commitment across the cancer community from physicians, patients, insurers, hospitals, and industry. A 2010 report by the Institute of Medicine described challenges to participation in trials by both physicians and patients and provided recommendations for revitalizing clinical trials conducted through the National Cancer Institute's Cooperative Group Program. ASCO has pledged its support for the full implementation of these recommendations. More broadly, ASCO recently outlined a bold vision for translational and clinical cancer research for the next decade and made recommendations to achieve that vision. Accelerating Progress Against Cancer: ASCO's Blueprint for Transforming Clinical and Translational Research, released in November, calls for a research system that takes full advantage of today's scientific and technologic opportunities and sets a high-level agenda for policy makers, regulators, and advocates. Cancer research has transformed cancer care in the past forty years, and this year's Clinical Cancer Advances illustrates how far we have come in the past year alone. We now have a tremendous opportunity to use today's knowledge and collaborate across all facets of cancer care to conquer this deadly disease. Michael P. Link, MD President American Society of Clinical Oncology.</abstract><cop>Alexandria, VA</cop><pub>American Society of Clinical Oncology</pub><pmid>22147736</pmid><doi>10.1200/JCO.2011.40.1919</doi><tpages>22</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0732-183X
ispartof Journal of clinical oncology, 2012-01, Vol.30 (1), p.88-109
issn 0732-183X
1527-7755
language eng
recordid cdi_proquest_miscellaneous_913317028
source MEDLINE; American Society of Clinical Oncology Online Journals; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Adult
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Biomarkers, Tumor - metabolism
Chemotherapy, Adjuvant
Child
Clinical Trials as Topic - trends
Drug Approval
Early Detection of Cancer - methods
Educational Status
Female
Genetic Predisposition to Disease
Health Care Reform
Health Policy - trends
Health Services Accessibility
Healthcare Disparities
Hospice Care
Humans
Immunotherapy
Male
Medical Oncology - trends
Medical sciences
Mutation
Neoplasms - diagnosis
Neoplasms - drug therapy
Neoplasms - metabolism
Neoplasms - mortality
Neoplasms - prevention & control
Precision Medicine
Primary Prevention - methods
Quality of Life
Radiotherapy, Adjuvant
Research - trends
Secondary Prevention - methods
Socioeconomic Factors
Terminal Care
Tomography, X-Ray Computed
Tumors
United States - epidemiology
title Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T11%3A30%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Cancer%20Advances%202011:%20Annual%20Report%20on%20Progress%20Against%20Cancer%20From%20the%20American%20Society%20of%20Clinical%20Oncology&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=VOGELZANG,%20Nicholas%20J&rft.date=2012-01-01&rft.volume=30&rft.issue=1&rft.spage=88&rft.epage=109&rft.pages=88-109&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.2011.40.1919&rft_dat=%3Cproquest_cross%3E913317028%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=913317028&rft_id=info:pmid/22147736&rfr_iscdi=true